News and Press | December 16, 2020

COVID-19 Pandemic Puts Squeeze on Pension Plans

Todd Tauzer, vice president and consulting actuary for Segal, recently spoke with The Wall Street Journal about COVID-19’s impact on pension plans.

Read the article.

COVID-19 Pandemic Puts Squeeze on Pension Plans

The hard choice facing pension managers: more risk or more money?

Pensions and other retirement-benefit programs have long struggled to figure out how to eliminate the gap between the assets on hand and cost of benefits promise to pay in future decades. Bond rates are expected to remain low resulting in fixed-income portfolios returning little. This concern continues to grow as investment returns fall.

The urgency of this issue is only rising amidst the pandemic, pushing retirement-fund managers across the country into action to keep shortfalls from growing. Such shortfalls aren’t a new industry phenomenon. According to Federal Reserve data, even before the pandemic, retirement and pension funds were already short trillions of dollars in assets required to pay future benefits.

Tauzer commented, “I wouldn’t be surprised if they continue to come down more in the next few years.” Lowering return expectations is politically difficult for pension funds because doing so increases expected shortfall between assets and liabilities, which often leads to higher costs for government employers and workers.

Asian Female Pharmacist Uses Computer To Check Inventory For A Drug

Designing and Negotiating Affordable Pharmacy Benefits

Learn how health plan sponsors can improve pharmacy benefit value through PBM contracting, formulary management and clinical oversight.
Focused Business Woman Working On Laptop Computer Reading

Many Retirement Plans Must Be Amended by December 31, 2026

Learn which retirement plans must be amended by December 31, 2026 and how SECURE Act discretionary and required amendments differ.
Man Self Injecting GLP 1 Weight Loss Medication Pen At Home

GLP-1s Have Disrupted the Market for Other Diabetes Drugs

Segal’s SHAPE data shows how rising GLP-1 use coincided with declines in insulin, Metformin and DPP-4 inhibitor use.

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.